tbuckley/cabot-search huggingface dataset:
Histopathology of Estrogen-Induced Tumors in Guinea Pigs
Authors: Eli M. Nadel, M. D.
Journal: JNCI Journal of the National Cancer Institute (1950)

Histopathology of Estrogen-Induced Tumors in Guinea Pigs Get access Eli M. Nadel, M. D. Eli M. Nadel, M. D. National Cancer Institute, National Institutes of Health, Public Health Service, Bethesda, Md., and the Department of Pathology, Washington University School of Medicine, St. Louis, Mo. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 5, April 1950, Pages 1043–1065, https://doi.org/10.1093/jnci/10.5.1043 Published: 01 April 1950 Article history Received: 13 October 1949 Published: 01 April 1950
Selective Inhibition Mediates the Sequential Recruitment of Motor Pools
Authors: Maarten F. Zwart, Stefan R. Pulver, James W. Truman, Akira Fushiki, Richard D. Fetter, Albert Cardona, Matthias Landgraf
Journal: Neuron (2016)

Locomotor systems generate diverse motor patterns to produce the movements underlying behavior, requiring that motor neurons be recruited at various phases of the locomotor cycle. Reciprocal inhibition produces alternating motor patterns; however, the mechanisms that generate other phasic relationships between intrasegmental motor pools are unknown. Here, we investigate one such motor pattern in the Drosophila larva, using a multidisciplinary approach including electrophysiology and ssTEM-based circuit reconstruction. We find that two motor pools that are sequentially recruited during locomotion have identical excitable properties. In contrast, they receive input from divergent premotor circuits. We find that this motor pattern is not orchestrated by differential excitatory input but by a GABAergic interneuron acting as a delay line to the later-recruited motor pool. Our findings show how a motor pattern is generated as a function of the modular organization of locomotor networks through segregation of inhibition, a potentially general mechanism for sequential motor patterns.
PD2-1-2: Involvement of the tumor suppressor ING2 gene in lung cancer
Authors: Elisabeth Brambilla, Damien Ythier, Romuald Binet, Damien Nissou, Delphine Larrieu, Laetitia Escales, Christian Brambilla, Sylvie Gazzeri, Rémy Pedeux
Journal: Journal of Thoracic Oncology (2007)
A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.
Authors: Bruno Sangro, Joong-Won Park, Christine Marie Dela Cruz, Jeffrey Anderson, Lixin Lang, Jaclyn Neely, James W Shaw, Ann-Lii Cheng
Journal: Journal of Clinical Oncology (2016)

TPS4147 Background: HCC is the fifth most prevalent cancer globally and the second-leading cause of cancer-related deaths. The high mortality rate is typically due to the late stage of disease at diagnosis and a lack of effective treatment options. Sorafenib, the only systemic agent approved to treat advanced HCC, has shown only a modest survival benefit. More effective treatment options are needed. Nivolumab, a fully human IgG4 monoclonal antibody programmed death receptor-1 (PD-1) inhibitor, has demonstrated overall survival (OS) benefit in pts with metastatic melanoma, non–small-cell lung cancer, and advanced renal cell carcinoma. Preliminary data from the CheckMate-040 trial suggest that nivolumab has clinical activity and is tolerable in pts with HCC, including those with hepatitis B or hepatitis C virus (HCV) infection.1 CheckMate-459 is a phase 3, randomized, open-label study (NCT02576509) designed to compare the efficacy of nivolumab and sorafenib in pts with advanced HCC. Methods: Eligibility criteria include age ≥ 18 years, histologically confirmed advanced HCC, ≥ 1 measurable untreated lesion, ECOG performance status of 0 or 1, and no prior systemic therapy. Additional criteria include completion of locoregional therapy for HCC ≥ 4 weeks prior to baseline scan and Child-Pugh class A. Pts with fibrolamellar, sarcomatoid HCC; mixed cholangiocarcinoma and HCC; or prior liver transplant will be excluded. An estimated 726 pts will be randomized 1:1 to receive nivolumab or sorafenib until disease progression or unacceptable toxicity. Pts will be stratified by etiology, vascular invasion and/or extrahepatic spread, and geography. CheckMate-459 began in Nov 2015; estimated primary completion date is May 2017. Primary objectives are OS and time to progression. Secondary objectives include overall response rate, progression-free survival, and evaluation of the relationship between PD-L1 expression and efficacy. Exploratory patient-reported measures, including effects of treatment on health status and quality of life, will also be evaluated. Reference:1El-Khoueiry, et al. J Clin Oncol. 2015;33(suppl):LBA 101. Clinical trial information: NCT02576509.
MTP19-01: T4 N0/N1 nonsmall cell lung cancer can be cured as a first line treatment with an expected five year survival rate as high as 43% provided a radical resection is performed
Authors: Philippe G. Dartevelle, Bedrettin Yildizeli, Elie Fadel, Sacha Mussot
Journal: Journal of Thoracic Oncology (2007)
Routine pelvic examinations have no confirmed benefits, US panel concludes
Authors: Michael McCarthy
Journal: BMJ (2016)

Evidence is insufficient to determine the benefits or harms of screening pelvic examinations in asymptomatic women who are not pregnant, the US Preventive Services Task Force (USPSTF) has concluded in draft recommendations.

The task force said that its literature review found inadequate evidence on the benefits of screening pelvic examinations for a wide range of gynecological conditions. “No studies were identified that evaluated the benefit of screening with pelvic examination on all-cause mortality, disease-specific morbidity or mortality, or quality of life,” the panel said.

“Overall, the current available evidence is insufficient for …
Gender differences in the outcome of community-acquired Staphylococcus aureus bacteraemia: a historical population-based cohort study
Authors: J. Smit, L.E. López-Cortés, A.J. Kaasch, M. Søgaard, R.W. Thomsen, H.C. Schønheyder, J. Rodríguez-Baño, H. Nielsen
Journal: Clinical Microbiology and Infection (2016)
Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib
Authors: Alessandra Trojani, Milena Lodola, Barbara Di Camillo, Giuseppe Rossi, Adele Capucci, Alessandra Perego, Enrico Maria Pogliani, Ester Orlandi, Alessandra Iurlo, Simona Malato, Paolo Corradini, Roberto Cairoli, Marco Bregni, Salvatore Artale, Enrica Morra, Ester Pungolino
Journal: Blood (2014)
Task-Oriented Rehabilitation Program for Stroke—Reply
Authors: Carolee Winstein, Steven Wolf, Alexander W. Dromerick
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology
Authors: Brian E. Sansbury, Matthew Spite
Journal: Circulation Research (2016)

Acute inflammation is a host-protective response that is mounted in response to tissue injury and infection. Initiated and perpetuated by exogenous and endogenous mediators, acute inflammation must be resolved for tissue repair to proceed and for homeostasis to be restored. Resolution of inflammation is an actively regulated process governed by an array of mediators as diverse as those that initiate inflammation. Among these, resolvins have emerged as a genus of evolutionarily conserved proresolving mediators that act on specific cellular receptors to regulate leukocyte trafficking and blunt production of inflammatory mediators, while also promoting clearance of dead cells and tissue repair. Given that chronic unresolved inflammation is emerging as a central causative factor in the development of cardiovascular diseases, an understanding of the endogenous processes that govern normal resolution of acute inflammation is critical for determining why sterile maladaptive cardiovascular inflammation perpetuates. Here, we provide an overview of the process of resolution with a focus on the enzymatic biosynthesis and receptor-dependent actions of resolvins and related proresolving mediators in immunity, thrombosis, and vascular biology. We discuss how nutritional and current therapeutic approaches modulate resolution and propose that harnessing resolution concepts could potentially lead to the development of new approaches for treating chronic cardiovascular inflammation in a manner that is not host disruptive.
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
Authors: Amita Patnaik, Mark A. Socinski, Matthew A. Gubens, Leena Gandhi, James Stevenson, Robert D. Bachman, Jennifer Bourque, Joy Yang Ge, Ellie Im, Shirish M. Gadgeel
Journal: Journal of Clinical Oncology (2015)

8011 Background: Pembro is a potent anti–PD-1 monoclonal antibody. IPI, an anti–CTLA-4 antibody, has shown activity in advanced NSCLC. In melanoma, combined anti–PD-1 and anti–CTLA-4 treatment has shown robust efficacy and manageable toxicity. We report interim results from a phase 1 study evaluating pembro + IPI in patients (pts) with recurrent NSCLC. Methods: Pts with stage IIIB/IV NSCLC that recurred after ≤ 2 prior regimens received pembro + IPI every 3 wk for 4 cycles followed by maintenance pembro. Based on emerging data from the nivolumab + IPI advanced NSCLC study, doses were reduced from 10 mg/kg to 2 mg/kg for pembro and from 3 mg/kg to 1 mg/kg for IPI). Primary end point was safety and incidence of dose-limiting toxicities (DLTs) in the first 3 wk of dosing. Response was assessed every 6 wk per RECIST 1.1 by investigator review. Results: As of Dec 2014,17 pts were enrolled: 3 at pembro 10 mg/kg + IPI 3 mg/kg, 3 at pembro 10 mg/kg + IPI 1 mg/kg, and 11 at pembro 2 mg/kg + IPI 1 mg/kg. No DLTs or dose modifications were reported for the 15 pts treated at the time of analysis. 10 pts experienced drug-related AEs (DRAEs); none led to discontinuation or death. There were 2 gr 3 DRAEs, both rash. Gr 2 DRAEs were diarrhea and vomiting (n = 2 each) and chills, cough, decreased appetite, decreased weight, dehydration, depression, dysphonia, fatigue, myalgia, pruritus, and pyrexia (n = 1 each). Responses were seen in all dose groups among the 11 pts on treatment for ≥ 6 wk at the time of analysis, including 1 CR (9%) and 5 PRs (45%) (Table); all pts achieved disease control. 12 pts remain on treatment (range, 6 + to 26 + wk); 3 pts discontinued for PD. Conclusions: Preliminary data from KEYNOTE-021 cohort D demonstrate an acceptable toxicity profile and robust antitumor activity for pembro + IPI in pts with recurrent NSCLC.The use of lower pembro and IPI doses did not appear to negatively impact efficacy. Clinical trial information: NCT02039674. Pembro 10 + IPI 3 n = 3 Pembro 10 + IPI 1 n = 3 Pembro 2 + IPI 1 n = 5 Total n = 11 CRa 1 (33%) 0 0 1 (9%) PRa 0 2 (67%) 3 (60%) 5 (45%) SD ≥6 wk 2 (67%) 1 (33%) 2 (40%) 5 (45%) ORR (CR+PR)a 1 (33%) 2 (67%) 3 (60%) 6 (55%) Disease control rate (CR+PR+SD ≥6 wk)a 3 (100%) 3 (100%) 5 (100%) 11 (100%) aRECIST v1.1 confirmed + unconfirmed.
P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)
Authors: S. Iwamoto, S. Hazama, H. Kin, H. Takemoto, K. Kobayashi, Y. Takahashi, M. Kobayashi, H. Maeda, N. Nagata, K. Oba, J. Sakamoto, H. Mishima
Journal: Annals of Oncology (2016)
Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders
Authors: O Brawman-Mintzer, R B Lydiard, M M Crawford, N Emmanuel, R Payeur, M Johnson, R G Knapp, J C Ballenger
Journal: American Journal of Psychiatry (1994)

The authors compared the distribution of somatic symptoms associated with generalized anxiety disorder in 28 patients with "pure" generalized anxiety disorder and 77 patients with generalized anxiety disorder plus comorbid current or lifetime psychiatric diagnoses. They found no significant differences in individual symptom endorsement between the two groups, indicating that the basic symptoms of generalized anxiety disorder are specific to the disorder itself.
Diabetes Among Asians and Native Hawaiians or other Pacific Islanders — United States, 2011–2014
Authors: Karen A. Kirtland, Pyone Cho, Linda S. Geiss
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

Asians and Native Hawaiians or other Pacific Islanders (NHPIs) are fast-growing U.S. minority populations at high risk for type 2 diabetes. Although national studies have described diabetes prevalence, incidence, and risk factors among Asians and NHPIs compared with non-Hispanic whites, little is known about state-level diabetes prevalence among these two racial groups, or about how they differ from one another with respect to diabetes risk factors. To examine state-level prevalence of self-reported, physician-diagnosed (diagnosed) diabetes and risk factors among Asians and NHPIs aged ≥18 years, CDC analyzed data from the 2011-2014 Behavioral Risk Factor Surveillance System (BRFSS). Among five states and Guam with sufficient data about NHPIs for analysis, the age-adjusted diabetes prevalence estimate for NHPIs ranged from 13.4% (New York) to 19.1% (California). Among 32 states, the District of Columbia (DC), and Guam that had sufficient data about Asians for analysis, diabetes prevalence estimates for Asians ranged from 4.9% (Arizona) to 15.3% (New York). In the five states and Guam with sufficient NHPI data, NHPIs had a higher age-adjusted prevalence of diabetes than did Asians, and a higher proportion of NHPIs were overweight or obese and had less than a high school education compared with Asians. Effective interventions and policies might reduce the prevalence of diabetes in these growing, high-risk minority populations.
Selective Modulation of the BMP Signaling Pathway Has Distinct Effects on Long-Term In Vitro Maintenance of Primitive Hematopoietic Progenitors in Human Umbilical Cord Blood.
Authors: Leah E. Colvin-Wanshura, Matthew S. Nelson, Elliot J. Stephenson, Shaukat A. Khan, Yonghong Xie, Pankaj Gupta
Journal: Blood (2005)
A Case of Oral Metastasis From Hepatocellular Carcinoma Displayed on 18F-FDG PET/CT Imaging
Authors: Lei Jiang, Taoying Gu, Fang Liu, Lijuan Luan, Hongcheng Shi
Journal: Clinical Nuclear Medicine (2015)

A 65-year-old man was diagnosed with hepatocellular carcinoma 4 years ago, for which he underwent interventional therapy and radiofrequency ablation after the right lobe partial hepatectomy. He was doing well, and an FDG PET/CT scan performed 1 year earlier did not reveal any hypermetabolic lesions. However, on recent examination, a soft tissue mass inside the oral cavity was found. 18F-FDG PET/CT imaging was performed to evaluate the possible metastasis. The images showed that the oral lesion was hypermetabolic. The pathology after biopsy confirmed oral metastasis from hepatocellular carcinoma.
Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC).
Authors: Michael Thomas Schweizer, Hao Wang, Brandon Luber, Rosa Maria Nadal, Avery N. Spitz, David Marc Rosen, Haiyi Cao, Emmanuel S. Antonarakis, Mario A. Eisenberger, Michael Anthony Carducci, Channing Judith Paller, Samuel R. Denmeade
Journal: Journal of Clinical Oncology (2016)

236 Background: We documented a paradoxical anti-tumor effect when castration-resistant prostate cancer patients were treated with intermittent, high-dose testosterone (i.e. BAT) [PMID: 25568070]. Since the adaptive increase in androgen receptor expression that follows chronic androgen deprivation therapy (ADT) may underlie this effect, we tested whether men with HS PC would also respond to BAT if given following a 6-month ADT lead-in. Methods: Men with asymptomatic HS PC and low metastatic burden (N = 20) (no visceral disease, ≤ 10 bone metastases, no lymph nodes &gt; 5 cm short axis diameter) or non-metastatic biochemically recurrent disease (N = 13) were enrolled. Following 6-months of ADT, those with a PSA &lt; 4 ng/ml went on to receive 2 cycles of BAT. A cycle of BAT was defined as intramuscular testosterone (T) cypionate or enanthate 400 mg on Days (D) 1, 29 and 57 followed by ADT alone D 85-169. ADT was continued throughout the study to allow for rapid cycling from near castrate to supraphysiologic range T following T injections. The primary endpoint was the percent of patients with a PSA &lt; 4 ng/ml after 2 cycles of BAT, with the study designed to reject a null rate of 40% at a one-sided alpha = 0.1. Secondary endpoints included quality of life (QOL) as measured by the SF-36, FACT-P, IIEF and IPSS surveys. Results: Twenty-nine of 33 patients received BAT following the ADT lead-in (1 withdrew consent, 3 had PSA &gt; 4 ng/ml). The primary endpoint was met, with 17/29 men (59%, lower bound 90% confidence interval = 45%) having a PSA &lt; 4 ng/ml after 2 cycles of BAT. Ten patients receiving BAT had RECIST evaluable disease, and 8 (80%) objective responses were observed (4 complete; 4 partial). Three patients progressed per RECIST criteria and 3 had unconfirmed progression on bone scan. Men treated with 6-months of ADT had improved QOL after the first cycle of BAT. The median improvement in SF-36, FACT-P, and IIEF total scores were 3.2 (range, -20 to 48; P = 0.21), 3.5 (range, -30 to 50; P = 0.04), and 10 (range, -4 to 59; P &lt; 0.001) points, respectively. There was no change in total IPSS score (median change 0 [range, -9 to 8; P = 0.87]). Conclusions: BAT demonstrated preliminary efficacy in men with HS PC following 6-months of ADT. BAT may improve QOL in men that have received ADT. Clinical trial information: NCT01750398.
Functional Analysis of the Subclonal Architecture of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) at a Single Cell Level
Authors: Bartosch Wojcik, Fabian Lang, Susanne Badura, Anja Vogel, Tamara Tesanovic, Thomas Oellerich, Timm Schroeder, J.H. Frederik Falkenburg, Monika Brüggemann, Oliver G. Ottmann, Michael A. Rieger
Journal: Blood (2014)
Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia.
Authors: Amy Pickar Abernethy, Jennifer S. Temel, David Currow, Lyon L. Gleich, John Friend
Journal: Journal of Clinical Oncology (2013)

TPS9649 Background: Cancer anorexia/cachexia is a debilitating and life-threatening complication of an underlying malignancy that may develop in up to 80% of terminally ill cancer patients. Cancer cachexia has a multifactorial pathogenesis and is manifested by accelerated losses of skeletal muscle and disproportionate losses of lean body mass (LBM). Anamorelin HCl is a ghrelin receptor agonist that has demonstrated significant increases in LBM, physical strength, and body weight in Phase II trials in patients with cancer cachexia. Through its ghrelin and growth hormone secretagogue activity, it displays both anabolic and appetite stimulating properties – two aspects vital to treating cancer anorexia/cachexia. Methods: HT-ANAM-301 (NCT01387269) and HT-ANAM-302 (NCT01387282), also known as ROMANA 1 and ROMANA 2, are double-blind, placebo-controlled, randomized (2:1 anamorelin HCl vs. placebo) Phase III trials in patients with non-small cell lung cancer (NSCLC) cachexia. Eligible patients must have unresectable Stage III or IV NSCLC and cachexia (weight loss of ≥5% body weight within prior 6 months or BMI &lt;20 kg/m 2 ). Patients receive once daily oral doses of anamorelin HCl (100 mg) or placebo for 12 weeks. Co-primary endpoints are the change from baseline in LBM as measured by DXA and in muscle strength as measured by handgrip strength. Secondary endpoints include change in body weight, overall survival, and quality of life (FACIT-F and FAACT questionnaires). For HT-ANAM-301 only, blood samples are collected at Week 6 for population pharmacokinetics. After 12 weeks of treatment, patients may continue in a separate 12-week safety extension study (HT-ANAM-303 [ROMANA 3] NCT01395914). At their last meeting (August 2012), the Independent Data Monitoring Committee suggested no safety issue and allowed the trials to continue as planned. Clinical trial information: NCT01387269, NCT01387282, NCT01395914.
The state and consequences of dermatology drug prices in the United States
Authors: Joerg Albrecht, Mark Lebwohl, Maryam M. Asgari, Daniel D. Bennett, Ashley Cook, Colby C. Evans, Lawrence J. Green, Julie A. Hodge, Arianne S. Kourosh, Mary E. Maloney, Leah M. Howard, Elise A. Olsen, Steven P. Rosenberg, Adam Rubin, Dow B. Stough, Susan C. Taylor, Bruce Alan Brod
Journal: Journal of the American Academy of Dermatology (2016)
Late Breaking Science502Hemopexin counteracts systolic dysfunction induced by heme overload503Inhibition of NF-kappa B suppressed inflammation induced by acute shear stress in endothelial cells: Implications for vein graft failure504Optical treatment of cardiac arrhythmias505Tachypacing-induced heart failure: a metabolomic investigation506Characterization of early left ventricle dysfunction in a relevant experimental model for human rheumatoid arthritis507Circadian rhythm in heart rate is due …
Authors: Can-Martin Sag, Alexander Ward, Claudia Crocini, Amy Watkins, Silvia Hayer, Yanwen Wang, Nikolai Rex, Stefan Wagner, Lucia De Franceschi, Francesca Vinchi, James Cimino, Sara Petrillo, Lorenzo Silengo, Fiorella Altruda, Lars S. Maier, Emilio Hirsch, Alessandra Ghigo, Emanuela Tolosano, Gianni D. Angelini, Sarah J. George, Mustafa Zakkar, Cecilia Ferrantini, Raffaele Coppini, Marina Scardigli, Ping Yan, Leslie M. Loew, Godfrey Smith, Elisabetta Cerbai, Corrado Poggesi, Francesco S. Pavone, Leonardo Sacconi, Stephanie Church, Paul Begley, David Eisner, Andrew Trafford, Garth Cooper, Milat Inci, Birgit Niederreiter, Tetyana Shvets, Kurt Redlich, Attila Kiss, Bruno Podesser, Alicia D'Souza, Anne Berit Johnsen, Servé Olieslagers, Annalisa Bucchi, Paula Da Costa Martins, Dario DiFrancesco, Halina Dobrzynski, Hugh D. Piggins, Mark R. Boyett
Journal: Cardiovascular Research (2016)
Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study
Authors: Ola Bratt, Linda Drevin, Olof Akre, Hans Garmo, Pär Stattin
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Familial prostate cancer risk estimates are inflated by clinically insignificant low-risk cancer, diagnosed after prostate-specific antigen testing. We provide age-specific probabilities of non-low- and high-risk prostate cancer.
Editorial: Can an Increase in Antineutrophil Cytoplasmic Autoantibody Titer Predict Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis?
Authors: Jung Hee Koh, Michael Joseph Kemna, Jan Willem Cohen Tervaert, Wan‐Uk Kim
Journal: Arthritis & Rheumatology (2016)